R9281
Rotigotine hydrochloride
≥98% (HPLC)
别名:
(−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H25NOS·HCl
化学文摘社编号:
分子量:
351.93
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1
SMILES string
Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2
InChI key
CEXBONHIOKGWNU-NTISSMGPSA-N
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
DMSO: >10 mg/mL
originator
UCB Inc.
storage temp.
room temp
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent.
Rotigotine is a dopamine receptor agonist with preference for D3 receptors over D2 and D1. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D2 agonist.
Features and Benefits
This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Aiping Wang et al.
Pharmaceutical research, 29(9), 2367-2376 (2012-05-03)
To prepare rotigotine loaded microspheres (RoMS) to achieve continuous dopaminergic stimulation (CDS) for the treatment of Parkinson's disease (PD) and investigate both the therapeutic benefit and inducibility of AIMs of administration of RoMS combination with L-DOPA in 6-OHDA-leisioned rats. Rotigotine
Heike Beneš et al.
Sleep medicine, 13(6), 589-597 (2012-04-17)
To assess the risk of augmentation under treatment with the transdermally delivered dopamine agonist rotigotine for restless legs syndrome (RLS). Experts in RLS augmentation retrospectively reviewed data from two double-blind, placebo-controlled 6-month trials (745 rotigotine and 214 placebo subjects, NCT00136045
Naoki Adachi et al.
Neuroscience letters, 662, 44-50 (2017-10-11)
Brain-derived neurotrophic factor (BDNF) critically controls the fate and function of the neuronal network and has received much attention as a target of many brain diseases. Dopaminergic system dysfunction has also been implicated in a variety of neuropsychiatric diseases. Rotigotine
In brief: transdermal rotigotine (Neupro).
The Medical letter on drugs and therapeutics, 54(1397), 68-68 (2012-08-22)
Elisabeth Dohin et al.
Expert opinion on pharmacotherapy, 14(1), 15-25 (2012-12-22)
This post-hoc analysis of a prospective open-label study investigated patients with restless legs syndrome (RLS) taking approved dosages (1, 2 or 3 mg/24 h) of rotigotine transdermal patch for up to 5 years. Following 6 weeks' double-blind treatment, patients with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持